08:00 , Mar 7, 2013 |  BC Innovations  |  Targets & Mechanisms

ALL emerges from relapse

Separate teams led by researchers from New York University and Columbia University have identified mutations in 5ʹ-nucleotidase cytosolic II that predict relapse, drug resistance and poor prognosis in acute lymphoblastic leukemia. 1,2 Inhibiting the enzyme...
08:00 , Feb 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) 5ʹ-Nucleotidase cytosolic II (NT5C2) In vitro studies suggest inhibiting NT5C2 could help treat chemotherapy-resistant ALL. In the first study, whole-exome sequencing...